Verification register Bio, Health & Neuro
Current reading
Readiness band and full integer triple
AI-assisted assembly · derived results
Readiness band
Watch
Primary summary from verified readiness
- Confidence
- 67% · fresh
- Computed at
- 2026-07-30T10:51:42.943246+00:00
- Claimed
- 45
- Reported
- 45
- Verified
- 40
- Gap
- +5
Public ambition and stated capability
Observed practitioner reporting
Independently supported evidence
Claimed leads verified
Evidence strength Critical
Decision
What the current evidence supports
Human editorial judgment · 2026-07-30
Track; not yet
- Why
- A statistically significant, opioid-sparing Phase 2b win published in NEJM (only the second original acute-pain drug paper there in 15 years) is a genuine, well-evidenced clinical milestone worth logging in Bio/Health surveillance. But it is a single-asset small-molecule drug with Phase 3 only 'planned' (not started) and no product/platform surface pragma.vision can act on today — appropriate to track, not adopt or build against.
- Next
- Re-check at Phase 3 initiation/readout or FDA filing for LTG-001; no pragma.vision platform integration action is warranted at Phase 2b stage
Constraints
Blockers
No named blocker is present in the current public projection.
Evidence summary
Derived counts
AI-assisted assembly
- Total
- 5
- Tier 1
- 0
- Tier 2
- 4
- Tier 3
- 1
- Supports
- 3
- Contradicts
- 1
- Context
- 1
- Latest observed
- 2026-07-30
Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.
Publication record
Revisions
Initial public reading
- 2026-07-30 Reading moved from watch to watch.